Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Creative Biolabs is one of the world’s leading contract organizations (CRO) that has extensive experience in preclinical drug discovery. Our employees are at the core of our success, with the ambition to improving health and increasing access to quality health solutions worldwide. We believe when curious, courageous and collaborative people like you are brought together, a big difference will be made for the development of innovate medicines.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant Human MIC-B produced in E.coli is a protein with 326 amino acid residues containing the extracellular domain of mature human MICB (amino acid residues Ala23 – Tyr312) and having a molecular mass of approximately 37 kDa.
Measured by its ability to bind MICB antibody in a ELISA.
Less than 1EU/μg of rHuMIC-B as determined by LAL method.
>95% by SDS-PAGE and HPLC analyses.
This lyophilized preparation is stable at 2-8°C, but should be kept at -20°C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8°C. For maximal stability, apportion the reconstituted preparation into working alire 0t -C to -70°C. Avoid repeated freeze/thaw cycles.
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at <-20°C. Further dilutions should be made in appropriate buffered solutions.
MIC-B (MHC class I chain-related gene B) is a transmembrane glycoprotein that functions as a ligand for human NKG2D. A closely related protein, MIC-A, shares 85% amino acid identity with MIC-B. These 2 proteins are distantly related to the MHC class I proteins. MIC-A and MIC-B (MIC-A/B) possess three extracellular immunoglobulin-like domains, but have no capacity to bind peptide or interact with β2-microglobulin. The genes encoding MIC-A/B are found within the major histocompatibility complex on human chromosome 6. The MIC-B locus is polymorphic with more than 15 recognized human alleles. MIC-A/B are minimally expressed on normal cells, but are frequently expressed on epithelial tumors and can be induced by bacterial and viral infections.MIC-A/B are ligands for NKG2D, an activating receptor expressed on NK cells, NKT cells, γδ T cells, and CD8+ αβ T cells. Recognition of MIC-A/B by NKG2D results in the activation of cytolytic activity and/or cytokine production by these effector cells. MIC-A/B recognition is involved in tumor surveillance, viral infections, and autoimmune diseases. The release of soluble forms of MIC-A/B from tumors down-regulates NKG2D surface expression on effector cells resulting in the impairment of anti-tumor immune response.
MHC class I receptor activity;molecular_function;protein binding.
AS; HLAB; HLAC; SPDA1; HLA-B73; HLA-B-7301; major histocompatibility complex, class I, B; ankylosing spondylitis; 1B53_HUMAN; HLA class I histocompatibility antigen, B-53; alpha chain [Precursor]; MHC class I antigen; B*53; Bw-53; HLAB;B'DT;B-12;B-21;B-5;HLA-B-5501;OTTHUMP00000034826; HLA class I histocompatibility antigen, B alpha chain; HLA class I histocompatibility antigen, B alpha chain precursor; Human transforming growth factor-beta induced gene product (BIGH3);mRNA, complete cds; MHC HLA-B cell surface glycoprotein;MHC class I HLA-B40MD alpha chain; MHC class I HLA-C antigen; MHC class I antigen B*13; MHC class I antigen HLA-B heavy chain; MHC class I antigen SHCHA; ankylosing spondylitis; leucocyte antigen C; leukocyte antigen class I-B; lymphocyte antigen; major histocompatibility complex class I B; major histocompatibility complex, class I, B.